FLT3 and acute myeloid leukemia: A double-blind randomized study showed that the addition of midostaurin to standard chemotherapy significantly improved overall and event-free survival in FLT3-positive AML patients; however, midostaurin was not beneficial as maintenance treatment after transplantation [18].